- Home
- PLX vs AXR Comparison
PLX vs AXR Comparison
Compare PLX & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- AXR
- Stock Information
- Founded
- PLX 1993
- AXR 1961
- Country
- PLX United States
- AXR United States
- Employees
- PLX N/A
- AXR 49
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- AXR Homebuilding
- Sector
- PLX Health Care
- AXR Real Estate
- Exchange
- PLX Nasdaq
- AXR Nasdaq
- Market Cap
- PLX 127.4M
- AXR 117.0M
- IPO Year
- PLX 1998
- AXR N/A
- Fundamental
- Price
- PLX $1.55
- AXR $22.00
- Analyst Decision
- PLX Strong Buy
- AXR
- Analyst Count
- PLX 1
- AXR 0
- Target Price
- PLX $15.00
- AXR N/A
- AVG Volume (30 Days)
- PLX 571.5K
- AXR 6.9K
- Earning Date
- PLX 08-14-2025
- AXR 09-12-2025
- Dividend Yield
- PLX N/A
- AXR N/A
- EPS Growth
- PLX N/A
- AXR 89.60
- EPS
- PLX 0.08
- AXR 2.37
- Revenue
- PLX $61,948,000.00
- AXR $49,694,000.00
- Revenue This Year
- PLX $14.53
- AXR $12.31
- Revenue Next Year
- PLX $75.77
- AXR $8.40
- P/E Ratio
- PLX $20.34
- AXR $9.61
- Revenue Growth
- PLX 62.79
- AXR N/A
- 52 Week Low
- PLX $0.89
- AXR $17.60
- 52 Week High
- PLX $3.10
- AXR $39.68
- Technical
- Relative Strength Index (RSI)
- PLX 47.97
- AXR 51.16
- Support Level
- PLX $1.47
- AXR $21.45
- Resistance Level
- PLX $1.57
- AXR $22.91
- Average True Range (ATR)
- PLX 0.07
- AXR 0.51
- MACD
- PLX -0.00
- AXR 0.01
- Stochastic Oscillator
- PLX 31.82
- AXR 58.22
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.